Background/Aim s: Hepatocellular carcinoma (HCC) is a prevalent form of primary liver cancer and the fifth leading cause of worldwide cancer mortality. Though early diagnosis of HCC is important, so far lack of effective biomarkers for early diagnosis of HCC has been a problem. In this study, we searched for potential functional biomarkers of alcoholic HCC by using metagenomics approach.
Methods Between September 2017 and April 2019, normal control (n=44), alcoholic liver cirrhosis (n=44), and alcoholic HCC (n=13) groups were prospectively enrolled and analyzed. Gut microbiota was analyzed using the 16S-based microbiome taxonomic profiling platform of EzBioCloud Apps and analyzing system.
Results There was a statistically significant difference among groups in diversity (P<0.05). In the comparison of phylum between cirrhosis and HCC, Proteobacteria were increased and Bacteroidetes were decreased. Firmicutes were not significantly different among the three groups. In the taxonomic profiling, relative abundance of Lactobacillus in the cirrhosis and HCC groups showed richness (P<0.05). In the biomarker analysis between cirrhosis and HCC, obiquinome Fe-S protein 3, global nitrogen regulator, Vesicle-associated membrane protein 7, toxin YoeB, peroxisome-assembly ATPase, and nitrogen oxide reductase regulator were differently expressed (P<0.001).
Conclusions Alcoholic HCC showed different expressions in the stool taxonomy and biomarker compared with that of cirrhosis and control. Therefore, new biomarkers using stool analysis for alcoholic HCC are necessary.
Hepatocellular carcinoma (HCC) surveillance is recommended when the annual incidence of HCC exceeds 1.5%. In 2018, several international guidelines included alternative surveillance modalities, such as computed tomography and magnetic resonance imaging (MRI), as alternatives for patients with inadequate surveillance with an ultrasound. Currently, abbreviated MRI selectively includes several key sequences and is emerging as an effective tool for HCC surveillance with reduced cost and scan time and the required diagnostic performance. The incidence of HCC substantially impacts the benefits of surveillance in terms of cost-effectiveness. Therefore, we need to individualize imaging surveillance of HCC, tailor screening, and determine risk-stratified strategies. The purpose of this article was to present a brief overview of the diagnostic performance and cost-effectiveness of liver MRI as an HCC surveillance tool.
Citations
Citations to this article as recorded by
Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis Su Jong Yu, Jeong-Ju Yoo, Dong Ho Lee, Su Jin Kim, Eun Ju Cho, Se Hyung Kim, Jeong-Hoon Lee, Yoon Jun Kim, Jeong Min Lee, Jae Young Lee, Jung-Hwan Yoon Biomedicines.2023; 11(2): 382. CrossRef
MRI features of histologic subtypes of hepatocellular carcinoma: correlation with histologic, genetic, and molecular biologic classification Ja Kyung Yoon, Jin-Young Choi, Hyungjin Rhee, Young Nyun Park European Radiology.2022; 32(8): 5119. CrossRef
Imaging features of hepatobiliary MRI and the risk of hepatocellular carcinoma development Jong-In Chang, Dong Hyun Sinn, Woo Kyoung Jeong, Jeong Ah Hwang, Ho Young Won, Kyunga Kim, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung-Woon Paik Scandinavian Journal of Gastroenterology.2022; 57(12): 1470. CrossRef
Potential of a Non-Contrast-Enhanced Abbreviated MRI Screening Protocol (NC-AMRI) in High-Risk Patients under Surveillance for HCC François Willemssen, Quido de Lussanet de la Sablonière, Daniel Bos, Jan IJzermans, Robert De Man, Roy Dwarkasing Cancers.2022; 14(16): 3961. CrossRef
Prognosis of hepatocellular carcinoma patients diagnosed under regular surveillance: potential implications for surveillance goal Joo Hye Song, Myung Ji Goh, Yewan Park, Joo Hyun Oh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik Scandinavian Journal of Gastroenterology.2021; 56(3): 274. CrossRef
Hepatocellular carcinoma (HCC) is heterogeneous in pathogenesis, phenotype and biological behavior. Various histopathological features of HCC had been sporadically described, and with the identification of common molecular alterations of HCC and its genomic landscape over the last decade, morpho-molecular correlation of HCC has become possible. As a result, up to 35% of HCCs can now be classified into histopathological variants, many of which have unique molecular characteristics. This review will provide an introduction to the variously described histopathological variants of HCC in the updated WHO Classification of Digestive System Tumors.
Citations
Citations to this article as recorded by
Computational pathology: A survey review and the way forward Mahdi S. Hosseini, Babak Ehteshami Bejnordi, Vincent Quoc-Huy Trinh, Lyndon Chan, Danial Hasan, Xingwen Li, Stephen Yang, Taehyo Kim, Haochen Zhang, Theodore Wu, Kajanan Chinniah, Sina Maghsoudlou, Ryan Zhang, Jiadai Zhu, Samir Khaki, Andrei Buin, Fatemeh Journal of Pathology Informatics.2024; 15: 100357. CrossRef
Characterization of lymphocyte‐rich hepatocellular carcinoma and the prognostic role of tertiary lymphoid structures Bokyung Ahn, Hee‐Sung Ahn, Jinho Shin, Eunsung Jun, Eun‐Young Koh, Yeon‐Mi Ryu, Sang‐Yeob Kim, Chang Ohk Sung, Ju Hyun Shim, JeongYeon Hong, Kyunggon Kim, Hyo Jeong Kang Liver International.2024; 44(5): 1202. CrossRef
Clinical‐Radiologic Morphology‐Radiomics Model on Gadobenate Dimeglumine‐Enhanced MRI for Identification of Highly Aggressive Hepatocellular Carcinoma: Temporal Validation and Multiscanner Validation Wanjing Zheng, Xiaodan Chen, Meilian Xiong, Yu Zhang, Yang Song, Dairong Cao Journal of Magnetic Resonance Imaging.2024;[Epub] CrossRef
Diagnostic Model for Proliferative HCC Using LI‐RADS: Assessing Therapeutic Outcomes in Hepatectomy and TKI‐ICI Combination Mengtian Lu, Zuyi Yan, Qi Qu, Guodong Zhu, Lei Xu, Maotong Liu, Jifeng Jiang, Chunyan Gu, Ying Chen, Tao Zhang, Xueqin Zhang Journal of Magnetic Resonance Imaging.2024;[Epub] CrossRef
Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma Catia Giovannini, Fabrizia Suzzi, Francesco Tovoli, Mariangela Bruccoleri, Mariarosaria Marseglia, Eleonora Alimenti, Francesca Fornari, Massimo Iavarone, Fabio Piscaglia, Laura Gramantieri Cancers.2023; 15(6): 1661. CrossRef
Non-alcoholic fatty liver disease: the pathologist’s perspective Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S302. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Three-dimensional multifrequency magnetic resonance elastography improves preoperative assessment of proliferative hepatocellular carcinoma Guixue Liu, Di Ma, Huafeng Wang, Jiahao Zhou, Zhehan Shen, Yuchen Yang, Yongjun Chen, Ingolf Sack, Jing Guo, Ruokun Li, Fuhua Yan Insights into Imaging.2023;[Epub] CrossRef
Lymphocyte-Rich Hepatocellular Carcinoma with Multiple Lymphadenopathy and Positive Epstein–Barr Virus Encoding Region Pin-Yi Wang, Yu-Hsuan Kuo, Ming-Jen Sheu, Hsing-Tao Kuo, Wen-Ying Lee, Yu-Ting Kuo, Su-Hung Wang, Zu-Yau Lin Case Reports in Hepatology.2023; 2023: 1. CrossRef
Genome-Wide Extrachromosomal Circular DNA Profiling of Paired Hepatocellular Carcinoma and Adjacent Liver Tissues Jianyu Ye, Peixin Huang, Kewei Ma, Zixin Zhao, Ting Hua, Wenjing Zai, Jieliang Chen, Xiutao Fu Cancers.2023; 15(22): 5309. CrossRef
Proliferative hepatocellular carcinomas in cirrhosis: patient outcomes of LI-RADS category 4/5 and category M Subin Heo, Hyo Jeong Kang, Sang Hyun Choi, Sehee Kim, Youngeun Yoo, Won-Mook Choi, So Yeon Kim, Seung Soo Lee European Radiology.2023;[Epub] CrossRef
Cellular heterogeneity and plasticity in liver cancer Lo-Kong Chan, Yu-Man Tsui, Daniel Wai-Hung Ho, Irene Oi-Lin Ng Seminars in Cancer Biology.2022; 82: 134. CrossRef
MRI features of histologic subtypes of hepatocellular carcinoma: correlation with histologic, genetic, and molecular biologic classification Ja Kyung Yoon, Jin-Young Choi, Hyungjin Rhee, Young Nyun Park European Radiology.2022; 32(8): 5119. CrossRef
Variant Hepatocellular Carcinoma Subtypes According to the 2019 WHO Classification: An Imaging-Focused Review Liang Meng Loy, Hsien Min Low, Jin-Young Choi, Hyungjin Rhee, Chin Fong Wong, Cher Heng Tan American Journal of Roentgenology.2022; 219(2): 212. CrossRef
Paraneoplastic syndromes in hepatocellular carcinoma: a review Yuki Ong, Cheong Wei Terence Huey, Vishalkumar Girishchandra Shelat Expert Review of Gastroenterology & Hepatology.2022; 16(5): 449. CrossRef
Morphomolecular Classification Update on Hepatocellular Adenoma, Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma Venkata S. Katabathina, Lokesh Khanna, Venkateswar R. Surabhi, Marta Minervini, Krishna Shanbhogue, Anil K. Dasyam, Srinivasa R. Prasad RadioGraphics.2022; 42(5): 1338. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Clinical and Molecular Hepatology.2022; 28(4): 583. CrossRef
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
Korean Journal of Radiology.2022; 23(12): 1126. CrossRef
Histomorphological Subtypes of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Review and Update Yoon Jung Hwang, Haeryoung Kim AJSP: Reviews and Reports.2022; 27(6): 234. CrossRef
A Case of Lymphocyte-Rich Hepatocellular Carcinoma in a Patient Who Was Treated for Colon Cancer Jae Won Song, Ho Soo Chun, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Young Nyun Park, Dai Hoon Han, Do Young Kim Journal of Liver Cancer.2021; 21(1): 69. CrossRef
HCC You Cannot See Vaishnavi Boppana, Sakshi Sahni, Joseph Glass, Christopher Chang, Denis M McCarthy Digestive Diseases and Sciences.2021; 66(7): 2185. CrossRef
An update on subtypes of hepatocellular carcinoma: From morphology to molecular Monika Vyas, Dhanpat Jain Indian Journal of Pathology and Microbiology.2021; 64(5): 112. CrossRef
HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy Sandeep Arora, Roberta Catania, Amir Borhani, Natally Horvat, Kathryn Fowler, Carla Harmath Abdominal Radiology.2021; 46(8): 3686. CrossRef
Gadoxetate-enhanced MRI Features of Proliferative Hepatocellular Carcinoma Are Prognostic after Surgery Hyo-Jin Kang, Haeryoung Kim, Dong Ho Lee, Bo Yun Hur, Yoon Jung Hwang, Kyung-Suk Suh, Joon Koo Han Radiology.2021; 300(3): 572. CrossRef
Radiologic Diagnosis of Hepatocellular Carcinoma Woo Kyoung Jeong The Korean Journal of Gastroenterology.2021; 78(5): 261. CrossRef
Update on Hepatocellular Carcinoma: a Brief Review from Pathologist Standpoint Nese Karadag Soylu Journal of Gastrointestinal Cancer.2020; 51(4): 1176. CrossRef
Use of immune checkpoint inhibitors (ICIs) in hepatocellular carcinoma (HCC) has been partially successful. However, most HCC patients do not respond to immunotherapy. HCC has been shown to induce several immune suppressor mechanisms in patients. These suppressor mechanisms include involvement of myeloid-derived suppressor cells, regulatory T-cells, functionally impaired dendritic cells (DCs), neutrophils, monocytes, and tumor associated macrophages. The accumulation of immunosuppressive cells may lead to an immunosuppressive tumor microenvironment as well as the dense fibrotic stroma which may contribute to immune tolerance. Our laboratory has been investigating different cellular mechanisms of immune suppression in HCC patients. In vitro as well as in vivo studies have demonstrated that abrogation of the suppressor cells enhances or unmasks tumor-specific antitumor immune responses. Two or three effective systemic therapies including ICIs and/or molecular targeted therapies and the addition of innovative combination therapies targeting immune suppressor cells may lead to increased immune recognition with a greater tumor response. We reviewed the literature for the latest research on immune suppressor cells in HCC, and here we provide a comprehensive summary of the recent studies in this field.
Citations
Citations to this article as recorded by
Higher Number of Tumor-Infiltrating PD-L1+ Cells Is Related to Better Response to Multikinase Inhibitors in Hepatocellular Carcinoma Ji Won Han, Ji Hoon Kim, Dong Hyun Kim, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jaegyoon Ahn, Hyun Yang, Pil Soo Sung Diagnostics.2023; 13(8): 1453. CrossRef
Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data Uasim Harkus, Miriam Wankell, Pranavan Palamuthusingam, Craig McFarlane, Lionel Hebbard Seminars in Cancer Biology.2022; 86: 799. CrossRef
Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma Pil Soo Sung Clinical and Molecular Hepatology.2022; 28(3): 333. CrossRef
The pathogenesis of hepatocellular carcinoma (HCC) is a complex process. During the last decade, advances in genomic technologies enabled delineation of the genomic landscape of HCC, resulting in the identification of the common underlying molecular alterations. The tumor microenvironment, regulated by inflammatory cells, including cancer cells, stromal tissues, and the surrounding extracellular matrix, has been extensively studied using molecular data. The integration of molecular, immunological, histopathological, and clinical findings has provided clues to uncover predictive biomarkers to enhance responses to novel therapies. Herein, we provide an overview of the current HCC genomic landscape, previously identified gene signatures that are used routinely to predict prognosis, and an immune-specific class of HCC. Since biomarker-driven treatment is still an unmet need in HCC management, translation of these discoveries into clinical practice will lead to personalized therapies and improve patient care, especially in the era of targeted and immunotherapies.
Citations
Citations to this article as recorded by
Comprehensive clinicopathologic study of alpha fetoprotein‐expression in a large cohort of patients with hepatocellular carcinoma Dirk Andreas Ridder, Arndt Weinmann, Mario Schindeldecker, Lana Louisa Urbansky, Kristina Berndt, Tiemo Sven Gerber, Hauke Lang, Johannes Lotz, Karl J. Lackner, Wilfried Roth, Beate Katharina Straub International Journal of Cancer.2022; 150(6): 1053. CrossRef
Two distinct stem cell‐like subtypes of hepatocellular carcinoma with clinical significance and their therapeutic potentials Sung Hwan Lee, Yun Seong Jeong, Sunyoung Lee, Bo Hwa Sohn, Ho Kyoung Hwang, Gi Hong Choi, Chang Moo Kang, Jin Sub Choi, Woo Jung Lee, Jae‐Ho Cheong, Hee Jin Jang, Ahmed Kaseb, Lewis Roberts, Sun Young Yim, Yun Shin Chun, Ju‐Seog Lee Cancer Communications.2022; 42(2): 179. CrossRef
Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways Hyuk Moon, Hyunjung Park, Min Jee Chae, Hye Jin Choi, Do Young Kim, Simon Weonsang Ro BMC Cancer.2022;[Epub] CrossRef
Tumor aggressiveness is independent of radiation quality in murine hepatocellular carcinoma and mammary tumor models Eshwar B. Udho, Shane M. Huebner, Dawn M. Albrecht, Kristina A. Matkowskyj, Linda Clipson, Catigan A. Hedican, Rachel Koth, Santina M. Snow, Emily L. Eberhardt, Devon Miller, Rachel Van Doorn, Genti Gjyzeli, Erin K. Spengler, Douglas R. Storts, Douglas H. International Journal of Radiation Biology.2021; 97(8): 1140. CrossRef
Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report Ji Eun Han, Hyo Jung Cho, Soon Sun Kim, Jae Youn Cheong Journal of Liver Cancer.2021; 21(2): 169. CrossRef
Update on Hepatocellular Carcinoma: a Brief Review from Pathologist Standpoint Nese Karadag Soylu Journal of Gastrointestinal Cancer.2020; 51(4): 1176. CrossRef
Hepatocellular carcinoma: new provisions of the WHO classification, 5th edition, 2019 E.M. Nepomnyashchaya, A.V. Shaposhnikov, E.A. Yurieva Arkhiv patologii.2020; 82(6): 36. CrossRef
Contrast-enhanced ultrasonography (CEUS) using microbubble ultrasonography contrast agent can show the vascular structure and unique contrast enhancement patterns of focal liver lesions, including hepatocellular carcinoma (HCC). CEUS shows three phases, similar to a vascular pattern on computer tomography (CT), and typical arterial enhancement and portal or late phase washout in HCC. CEUS can show real-time images without nephrotoxicity or radiation hazard and can be used as guidance for loco-regional treatment and estimation of treatment response of HCC. In addition, some data recently revealed the usefulness of CEUS in the early estimation of response to anti-cancer pharmacological (i.e., sorafenib) therapy in advanced HCC. Although CEUS has limitations in clinical practice and more investigation is needed for its validation, it is recommended as a main diagnostic modality in a few major clinical practice guidelines for HCC. Thus, greater understanding of CEUS is necessary to extend its application in real practice for diagnosis and management of diseases.
Citations
Citations to this article as recorded by
Perfluorobutane-Enhanced Ultrasound for Characterization of Hepatocellular Carcinoma From Non-hepatocellular Malignancies or Benignancy: Comparison of Imaging Acquisition Methods Seungchul Han, Se Woo Kim, Sungeun Park, Jeong Hee Yoon, Hyo-Jin Kang, Jeongin Yoo, Ijin Joo, Jae Seok Bae, Jeong Min Lee Ultrasound in Medicine & Biology.2023; 49(10): 2256. CrossRef
Mixed hepatocellular carcinoma and cholangiocarcinoma (HCC-CC) are rare tumors, and the risk factors associated with them are not well understood yet. Moreover, the diagnosis of mixed HCC-CC can be complicated due to the difficulty in distinguishing mixed HCC-CC from HCC and intrahepatic CCC on radiological images. Serum tumor markers are useful when the radiological images are inconclusive. It remains unclear whether the prognosis of mixed HCC-CC differs from that of HCC. However, several studies have reported that the tumor recurrence and patient survival rates of mixed HCC-CC were similar to those of HCC after liver transplantation (LT) and liver resection. In this paper, we report that LT in patients with mixed HCC-CC achieves outcomes which are similar to those seen in LT for HCC. Therefore, the diagnosis of mixed HCC-CC should not be considered as a contraindication for LT.
Citations
Citations to this article as recorded by
Liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma: A multicenter study Jongman Kim, Dong-Jin Joo, Shin Hwang, Jeong-Moo Lee, Je-Ho Ryu, Yang-Won Nah, Dong-Sik Kim, Doo-Jin Kim, Young-Kyoung You, Hee-Chul Yu World Journal of Gastrointestinal Surgery.2023; 15(7): 1340. CrossRef
The Role of Immunosuppression for Recurrent Cholangiocellular Carcinoma after Liver Transplantation Safak Gül-Klein, Paulina Schmitz, Wenzel Schöning, Robert Öllinger, Georg Lurje, Sven Jonas, Deniz Uluk, Uwe Pelzer, Frank Tacke, Moritz Schmelzle, Johann Pratschke, Ramin Raul Ossami Saidy, Dennis Eurich Cancers.2022; 14(12): 2890. CrossRef
Although post-transplantation lymphoproliferative disease (PTLD) after liver transplantation is very rare, its prognosis is worse than that of PTLD following other types of solid organ transplantation. Here, we report a rare case of early onset polymorphic PTLD in a graft liver occurring five months after deceased-donor liver transplantation due to hepatocellular carcinoma and hepatitis C virus infection. Initially, findings from contrast-enhanced magnetic resonance imaging mistakenly suspected the lesion was a necrotizing abscess with central necrosis. However, 18F-fluorodeoxyglucose positron emission tomography and biopsy findings confirmed an Epstein-Barr virus (EBV)-associated, B cell type polymorphic PTLD with central necrosis. Our case suggests regular monitoring of EBV serologic status for liver transplant recipients who were initially in an EBV seronegative state. Although early-onset PTLD is very rare after liver transplantation, PTLD should be suspected when recipients show the seroconversion for EBV proteins and the development of new tumors with various clinical presentations.
The treatment options available for patients with hepatocellular carcinoma (HCC) with portal vein invasion (PVI) include sorafenib, transarterial radioembolization (TARE), radiation therapy (RT), transarterial chemoembolization with RT, and proton beam irradiation. Herein, we present a case of HCC with segmental PVI that was managed via TARE. The patient had a 4 cm HCC that invaded the segment VIII portal vein branch without extrahepatic spread. Liver function was Child-Pugh grade A, and performance status was good. TARE was performed without any adverse events, and a radiological complete response (CR) was achieved. Thereafter, the patient was followed-up every 3-6 months without any further treatment, and the CR was maintained for >3 years. Therefore, TARE may be a useful alternative therapeutic option for patients with HCC exhibiting segmental PVI.
A 54-year old man diagnosed with advanced hepatocellular carcinoma began treatment with sorafenib. After 3 weeks of treatment, he complained of abdominal pain and nausea. Abdominal sonography showed multiple hepatic lesions only. Serum amylase and lipase levels were 35 U/L and 191 U/L, respectively. The patient was diagnosed with sorafenib-induced acute pancreatitis. After 10 days of discontinuing sorafenib he still complained of nausea and loss of appetite. Esophagogastroduodenoscopy showed a large bulging lesion, which was suspected to cause extrinsic compression on the high body of the gastric anterior wall. Computed tomography scan revealed a cystic lesion, 8.3 cm in size, in the pancreatic tail, suggesting a pancreatic pseudocyst. After the withdrawal of sorafenib, systemic chemotherapy with Adriamycin and cisplatin was administered. Four months after the discontinuation of sorafenib, the size of the pancreatic pseudocyst decreased from 8.3 cm to 3 cm. The patient's symptoms were also relieved.
Hepatocellular carcinoma (HCC) involving the inferior vena cava (IVC) and/or right atrium (RA) is a rare and intractable disease. A standard treatment has not been established yet, owing to the rarity of disease and difficulties in the therapeutic treatment. Herein, we report the case of a patient who had recurrent HCC (after a prior lobectomy) involving both IVC and RA and underwent multimodality treatments including external beam radiotherapy and transarterial chemotherapy, followed by sorafenib treatment. The disease was well controlled with local treatments and sustained for 7 years until last follow-up after the systemic treatments. Our case shows a possibility of long-term survival for patients affected by HCC involving IVC and/or RA, after a rigorous multimodality treatment strategy.
Hepatic solitary fibrous tumors (SFTs) are mostly benign and rare because of information regarding the clinical symptoms, treatment, and prognosis of their malignant forms is currently lacking. A literature review concerning malignant SFTs revealed that there were a few cases where patients experienced abdominal right upper quadrant (RUQ) pain as their first clinical symptom, and metastases were found after being diagnosed with hepatic SFT. Here, we report a patient who was previously healthy without any clinical symptoms such as RUQ pain or weight loss, but had the appearance of a metastatic mass as the first clinical presentation before a primary hepatic SFT was detected.
Citations
Citations to this article as recorded by
A Case of Hepatic Malignant Solitary Fibrous Tumor: A Case Report and Review of the Literature Zhiyan Fu, Evita B. Henderson-Jackson, Barbara A. Centeno, Gregory Y. Lauwers, Mihaela Druta, Daniel A. Anaya, Yukihiro Nakanishi, Samir Sami Amr Case Reports in Pathology.2023; 2023: 1. CrossRef
Proton beam therapy (PBT) is one of the advances in radiotherapy techniques, which enables dose escalation with lower probability of radiation-induced liver or gastrointestinal injuries. However, the chest wall proximal to the tumor can be affected by high dose irradiation. Here, we report on a 58-year-old male patient who presented with huge hepatocellular carcinoma, received treatment with transarterial chemoembolization and PBT, and developed severe chest wall pain due to radiation-induced myositis. The patient’s symptoms were controlled by oral steroids.
Citations
Citations to this article as recorded by
Pectoralis Major Radiation Myonecrosis After Lung Stereotactic Body Radiation Therapy Jason Gurewitz, Anand Mahadevan, Benjamin T. Cooper Practical Radiation Oncology.2023;[Epub] CrossRef
Current role of proton beam therapy in patients with hepatocellular carcinoma Gyu Sang Yoo, Jeong Il Yu, Hee Chul Park International Journal of Gastrointestinal Intervention.2021; 10(4): 175. CrossRef
Background/Aim s: Tenofovir disoproxil fumarate (TDF) is potentially nephrotoxic in chronic hepatitis B patients. Hepatocellular carcinoma (HCC) patients treated using transarterial chemoembolization (TACE) are at an increased risk of renal injury. The aim of this study was to determine whether TDF is associated with more renal adverse events than entecavir (ETV) in HCC patients treated with TACE.
Methods In this retrospective single-center study, we selected 53 HCC patients who were treated with TDF from January 2012 to July 2013 and had their first TACE procedure in the same period. These patients were matched by age and sex to patients treated with ETV.
Results There were no significant differences in baseline characteristics, including HCC factors, and nephrotoxic drug use, between the two groups. The median follow-up period was 17.0 and 20.0 months for the TDF and ETV groups, respectively. There was no difference during the follow-up period between the TDF and ETV groups in the increase in creatinine over 0.5 mg/dL (17.0% and 17.0%, P=1.00, respectively) and the decrease in eGFR over 25% (43.4% and 41.5%, P=0.84, respectively). Multivariate analysis revealed that Child-Pugh class over B (hazard ratio [HR], 7.30; 95% confidence interval [CI] 2.79-19.10; P<0.01) was associated with increase in creatinine, and Child-Pugh class over B (HR, 82.74; 95% CI 12.31-555.83; P<0.01) and Barcelona-Clinic Liver Cancer stage over B (HR, 14.93; 95% CI 1.60-139.51; P=0.02) were associated with decrease in eGFR.
Conclusions TDF has comparable safety to that of ETV for HCC patients undergoing TACE.
Citations
Citations to this article as recorded by
Big Data Information under Proportional Hazard Mathematical Model in Analysis of Hepatitis B Virus Infection Data of Patients with Interventional Liver Cancer through Antiviral Therapy of Entecavir Yichi Zhang, Shuai Zhao, Han Ding, Xiaoling Song, Huijie Miao, Xuya Cui, Jian Wang, Bing Han, Enas Abdulhay Journal of Healthcare Engineering.2021; 2021: 1. CrossRef
Background/Aim s: Sorafenib is the standard treatment for patients with advanced hepatocellular carcinoma (HCC). We aimed to investigate the prognosis predictors and the role of second-line cytotoxic systemic chemotherapy (CSC) in patients with advanced HCC after sorafenib discontinuation in the pre-regorafenib era.
Methods From 2007 to 2015 in the pre-regorafenib era, the medical records of 166 HCC patients, who had permanently discontinued sorafenib, were retrospectively reviewed. For further analysis of survival factors after sorafenib treatment failure, we compared the survival of patients who had maintained liver function after second-line treatment with the best supportive care (BSC) group and selective BSC (SBSC) group.
Results After discontinuation of sorafenib, median overall survival (OS) was 2.8 (1.9-3.7) months. The OS in patients who discontinued sorafenib due to adverse effect, progression, and poor clinical condition were 5.5 (2.4-8.6), 5.5 (2.2-8.9), and 0.9 (0.5-1.3) months, respectively (P<0.001). The independent predictive factors of survival after sorafenib failure were serum level of bilirubin and albumin, α-fetoprotein, discontinuation cause, and second-line CSC. In comparison with survival between second-line CSC and BSC group, the CSC group showed better survival outcome compared to the BSC group (10.6 vs. 1.6 months, P<0.001) and SBSC group (10.6 vs. 4.2 months, P=0.023).
Conclusions The survival after sorafenib failure in patients who discontinued sorafenib due to progression and adverse effects was significantly better than in those who discontinued treatment due to clinical deterioration. In the pre-regorafenib era, patients who received second-line CSC showed better survival than those who received only supportive care after sorafenib failure.